Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845533 | 0.91 | MTHFD2 (0.35) | HTR2BMTHFD2MGLL | |
| SCHEMBL22845334 | 0.88 | GRM5 (0.32) | GRM5MGLL | |
| SCHEMBL22845517 | 0.86 | CXCR4 (0.33) | GRM5 | |
| SCHEMBL22845502 | 0.86 | GRM1 (0.34) | GRM5PARP1 | |
| SCHEMBL22845232 | 0.85 | GRM1 (0.34) | GRM5 | |
| SCHEMBL22845444 | 0.84 | MAPT (0.34) | GRM5 | |
| SCHEMBL22845478 | 0.84 | LMNA (0.36) | — | |
| SCHEMBL24483796 | 0.81 | MTHFD2 (0.36) | MTHFD2MGLL | |
| SCHEMBL22845442 | 0.80 | GRM5 (0.34) | GRM5 | |
| SCHEMBL24173421 | 0.80 | ALDH1A1 (0.36) | PARP1MTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | HTR2B 2013/4885GRM5 3636/4885TNKS 1901/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | HTR2B 2013/4885GRM5 3636/4885TNKS 1901/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | HTR2B 2013/4885GRM5 3636/4885TNKS 1901/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | HTR2B 2013/4885GRM5 3636/4885TNKS 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.